The estimated Net Worth of Health, Inc. Harrow is at least $20.1 Milion dollars as of 12 April 2021. Health Harrow owns over 1,518,000 units of Eton Pharmaceuticals stock worth over $9,493,780 and over the last 4 years Health sold ETON stock worth over $10,626,000.
Health has made over 1 trades of the Eton Pharmaceuticals stock since 2021, according to the Form 4 filled with the SEC. Most recently Health sold 1,518,000 units of ETON stock worth $10,626,000 on 12 April 2021.
The largest trade Health's ever made was selling 1,518,000 units of Eton Pharmaceuticals stock on 12 April 2021 worth over $10,626,000. On average, Health trades about 1,518,000 units every 0 days since 2021. As of 12 April 2021 Health still owns at least 1,982,000 units of Eton Pharmaceuticals stock.
You can see the complete history of Health Harrow stock trades at the bottom of the page.
Health's mailing address filed with the SEC is 102 WOODMONT BLVD. SUITE 610, , NASHVILLE, TN, 37205.
Over the last 6 years, insiders at Eton Pharmaceuticals have traded over $20,773,599 worth of Eton Pharmaceuticals stock and bought 488,500 units worth $3,287,585 . The most active insiders traders include Management Inc. Opaleye, Mark L Baum a Health, Inc. Harrow. On average, Eton Pharmaceuticals executives and independent directors trade stock every 61 days with the average trade being worth of $746,905. The most recent stock trade was executed by Sean Brynjelsen on 22 September 2022, trading 10,000 units of ETON stock currently worth $21,000.
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Eton Pharmaceuticals executives and other stock owners filed with the SEC include: